OLY (ASX) Ann: Hemp Trial Farm Harvest Update

OLY

Click for more information

0.00%

4.0¢ olympio metals limited

First 78 Last

Share
Profile

Follow
twmochi

880 Posts.

156

23/10/19

14:46

Post #: 41032129
Share

Originally posted by moorookamick: ↑

The CEO has been over cautious so far in all his media appearances, IMO, by prefacing his commentary with warnings about the risks of farming.
This ,IMO, has made investors wary and unlikely to open up wallets until they see our cash in the bank. ( just listen to his video/tv presentations)

This is the opposite to what normally happens. Mr Market nearly always looks forward (rather than "wait & see" ) so that by the time
that money is in the bank, the market will have already factored -in that in share price and then looks forward to next year. Not so with CLI.

IMO, the CEO should have emphasised CLI's strengths over that of the average Hemp farrmer by promoting the features and benefits of
CLI's technology, agronomy & its hemp expert employees & its selection of strains; all to Manage/Minimise Risk and optimise harvest
returns. We are an ASX listed company and risk management is a prominent requirement of our ASX listing.

The CEO should give reguluar updates on CBD biomass pricing not alone to indicate that he is on top of his game, but also to
give prophets of doom less wiggle room on social media. It's all about being in control of the business and being ahead of the game, IMO.

This is an emerging buisness area that investors & the public generally know little about and CEOs have to be out there promoting their companies and their companies" prospects at every opportunity.
No one else will do it for them.

We pay our CEO $350K P/A with benefits and the opportunity to lift that to $1 million if harvest
revenue is over $45 million AUD.That is generous for a company with a Mkt Cap of $23 mil odd.

Expand

wouldn’t call it “over cautious”. More like being realistic about the risks.

Originally posted by DoriansMirror: ↑

I'm not worried in the slightest, but it is odd that the share price is going backwards as much as it is given the impressive harvest update.

Expand

CLI Price at posting: 5.3¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

OJC

SPC to merge with Original Juice Co and Nature One Dairy

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 93 more messages in this thread...

First 78 Last

Add OLY (ASX) to my watchlist

(20min delay)
Last 4.0¢		Change 0.000(0.00%)		Mkt cap ! $3.439M

Open	High	Low	Value	Volume
4.0¢	4.0¢	4.0¢	$3.912K	97.81K

Buyers (Bids)

No.	Vol.	Price($)
1	30000	3.8¢

Sellers (Offers)

Price($)	Vol.	No.
4.4¢	135127	1

View Market Depth

No.	Vol.	Price($)
1	30000	0.038
1	72572	0.036
1	2000000	0.015
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.044	135127	1
0.047	8701	1
0.090	29362	1
0.095	25000	1
0.100	250402	2

Last trade - 14.26pm 02/10/2024 (20 minute delay)

OLY (ASX) Chart

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

SPC to merge with Original Juice Co and Nature One Dairy

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

SPC to merge with Original Juice Co and Nature One Dairy

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News